NovoLog
 |
|
| Clinical data | |
|---|---|
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a605013 |
| Pregnancy category |
|
| Routes of administration |
Subcutaneous |
| ATC code | A10AB05 (WHO) |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number |
116094-23-6 
|
| PubChem (CID) | 16132418 |
| DrugBank |
DB01306 
|
| ChemSpider | none |
| UNII |
D933668QVX
|
| KEGG |
D04475
|
| ChEMBL |
CHEMBL1201496
|
| Chemical and physical data | |
| Formula | C256H381N65O79S6 |
| Molar mass | 5825.8 g/mol |
|
(what is this?)
|
|
Insulin aspart is a fast-acting insulin analog marketed by Novo Nordisk as NovoLog/NovoRapid. It is a manufactured form of human insulin; where a single amino acid has been exchanged. This change helps the fast-acting insulin analog be absorbed quickly into the bloodstream. As a result, it starts working in minutes, which allows one to take insulin and eat right away. Fast-acting insulin analogs are considered to act similarly to the way insulin is released in people without diabetes mellitus.
Novolog allows for a flexible dosing schedule, which allows patients to adjust their insulin according to any changes in their eating habits.
The safety and efficacy of insulin aspart (NovoLog/NovoRapid) in real-life clinical practice was evaluated in the A1chieve study.
It was created through recombinant DNA technology so that the amino acid, B28, which is normally proline, is substituted with an aspartic acid residue. This analog has increased charge repulsion, which prevents the formation of hexamers, to create a faster-acting insulin. The sequence was inserted into the yeast genome, and the yeast expressed the insulin analog, which was then harvested from a bioreactor.
According to JDRF, insulin aspart was approved for marketing in the United States by the Food and Drug Administration in June 2000.
The components of insulin aspart are as follows:
The pH of insulin aspart is 7.2–7.6.
The onset of action is approximately 15 minutes, the peak action is reached in 45–90 minutes, and the duration is 3–5 hours. However, as with all insulin, these numbers are based on averages, and vary between individuals due to blood flow, injection site, temperature and exercise.
It has been debated whether or not insulin aspart (or NovoLog/NovoRapid) should be kept refrigerated at all times. The manufacturer claims it can last 28 days without refrigeration, as long as it is kept below 86 °F / 30 °C. Above these temperatures, the potency of the insulin quickly degrades, rendering it less effective.
...
Wikipedia